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Introduction
Hepatitis C virus (HCV) infection is a disease with a sig-
nificant global impact. According to the World Health Or-
ganization (WHO) data, 71 million people worldwide are 
infected with HCV [1]. About 700,000 people die annually 
from HCV complications, including cirrhosis, hepatocel-
lular carcinoma (HCC), liver failure. In Western European 
countries, approximately 5 million people are infected with 
HCV, 40% of whom are in the stage of liver cirrhosis and 
30% are candidates for liver transplant [1, 2]. 
In the Republic of Moldova the prevalence of HCV in-
fection in the general population was estimated at 4.5-5.0%, 
with the prevalence of genotype (GT) 1b – 98% [3-5]. Ac-
cording to the cumulative data, at the end of 2016 in the Re-
public of Moldova, there were 15.400 people infected with 
HCV [6, 7]. At the same time, in the last years, there is an 
increase in the prevalence of cirrhosis through HCV from 
21.4 (2005) to 52.8 (2014) cases / 100.000 inhabitants [5].   
 Due to the fact that most cases (about 80%) are asymp-
tomatic, the actual incidence of HCV infection is much 
higher.
After HCV infection, the rate of chronicization is 55-
85%, and the rate of development of cirrhosis after 20 years 
after infection is 15-30% for infected persons after the age 
of 40 [2, 8]. The evolution of the disease is not linear; the 
progression of fibrosis is accelerated after the age of 50, re-
gardless of the infection [9, 10]. Patients with cirrhosis and 
HCV have an annual risk of decompensation of 3-5%, a risk 
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Abstract
Background: Hepatitis C virus (HCV) infection has a significant worldwide impact. Patients with hepatic cirrhosis with HCV have an annual risk of 
decompensation of 3-5%, a risk of developing hepatocellular carcinoma between 1.4-6.9% and a risk of mortality of 2% / year. Therefore, the treatment 
of chronic HCV infection is a priority for patients with severe hepatic fibrosis and cirrhosis.  The emergence and approval of direct-acting antivirals 
(DAA) in recent years have revolutionized antiviral therapy, especially for patients with liver cirrhosis. Following numerous studies it has been found 
that, this treatment is well tolerated by these patients. The combination of DAA from different groups has a potent enhancing effect, and the sustained 
viral response (SVR) rate reaches up to 85-98% in patients with liver cirrhosis. In general, the chance of performing SVR with DAA in patients with 
compensated cirrhosis (Child-Pugh A) is comparable to non-cirrhotic patients. However, there is a risk for decompensation and acute liver failure during 
and after treatment. Patients with decompensated liver cirrhosis and advanced liver fibrosis may have greater benefit from antiviral therapy after liver 
transplantation.
Conclusions:  The data obtained from the analyzed studies suggest that DAA antiviral therapy prevents the progressive evolution of the disease towards 
hepatocellular carcinoma or decompensation. At the same time, a correct therapeutic approach and a permanent monitoring of these patients can improve 
the quality of life, significantly prolonging the years of life.
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of developing HCC between 1.4-6.9% and a risk of morta-
lity of 2% / year [11-13].
In the context of the exposed data and the fact that the 
majority of patients take non-clinical forms, we can con-
clude that, from an epidemiological point of view, HCV is 
a problem, which has a negative impact on public health. 
Thus, the objectives proposed by WHO, included in the 
strategy for Global Health 2015-2030, are to increase the 
percentage of people tested for hepatitis C from 20% to 90% 
and those treated from 7% to 80% [1].
Direct-acting antiviral (DAA) treatment
Until hepatitis C was identified as an agent of non-A 
non-B hepatitis, Interferon (IFN) – alpha contributed to the 
normalization of transaminases and to the improvement of 
liver histology in some patients. Over time, the sustained 
virus response rate (VRR) increased from 5-20% in inter-
feron monotherapy, to 40-50% in the combination of IFN 
and ribavirin (RBV) [14].
Due to the limited efficacy and secondary extensive side 
effects of standard pegylated alpha – IFN (PEG) and RBV 
antiviral combination therapy, new antiviral drugs were 
needed.
The opportunity to administer direct-acting antiviral 
drugs (DAAs) is a substantial advantage in the treatment 
of chronic HCV infection, having the possibility of oral ad-
ministration, short duration of treatment, high sustained 
viral response (SVR), decreased liver stiffness, improved 
liver function, and minimal side effects [15, 16]. The combi-
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nation of DAA from different groups has an enhanced po-
tentiation effect, and the SVR rate reaches up to 85-98% in 
patients with cirrhosis [17, 18, 19].
 The data obtained from the analyzed studies suggest 
that such treatments can extend the life span of the cir-
rhotic patients, preventing the progressive evolution of the 
disease towards HCC or decompensation. Thus, patients 
with an advanced degree of fibrosis and an increased risk of 
liver complications, as well as those with severe extrahepatic 
manifestations will have priority over immediate treatment, 
using the most advantageous therapeutic options.
A correct therapeutic approach and a permanent moni-
toring of these patients can improve the quality of life, sig-
nificantly prolonging the life years.
Although there are still barriers that prevent the com-
plete eradication of HCV infection, mutual international ef-
forts to overcome them determine optimism regarding the 
future of treatment for this disease.
Treatment with DAA in cirrhosis with HCV infection: 
objectives, response to treatment, monitoring, adverse 
events
Liver cirrhosis represents the final evolutionary stage 
of any liver disease, being the consequence of destroying 
liver cells and reducing the ability of liver tissue to regener-
ate. The rate of chronicization and progression to cirrhosis 
is correlated with the age of infection (greater than 40-50 
years), male sex, presence of HBV / HIV coinfection, alco-
hol consumption, severity of liver fibrosis, presence of ste-
atosis [20-22]. For people with chronic infection, the risk of 
cirrhosis is between 15 and 30% for a period of 20 years [9].
At the same time, a diagnosis of compensated cirrhosis 
is associated with a 4.7 times higher risk of death compared 
to the general population, and decompensated cirrhosis is 
associated with a 9.7 times higher risk [22, 23].
The emergence and approval of DAA in recent years 
have revolutionized antiviral therapy, especially for patients 
with cirrhosis. Following numerous studies, it has been 
found that this treatment is well tolerated by patients with 
advanced liver disease [24, 25]. The current therapeutic pos-
sibilities have the advantage of being highly effective, and 
the main purpose of DAA therapy is to eradicate the infec-
tion as early as possible and to prevent the evolution of the 
disease in order not to reach the advanced stages of the di-
sease.
Before making the decision in favor of a particular treat-
ment regimen with DAA, several factors that may influence 
this therapy should be considered. First, the HCV genotype 
must be determined. Most DAA regimes are available and 
active against GT1. Second, previous antiviral therapies 
should be considered. Patients with relapse or unrespon-
siveness after treatment with PEG-INT and RBV still have 
high chances of viral eradication. However, previous treat-
ments followed by DAA may be associated with resistance, 
which may influence the outcome of therapy with other 
DAA regimens [24, 25]. Here, resistance analysis is recom-
mended to select an effective DAA combination. Also, the 
interaction between the drugs administered in the asso-
ciated diseases and those of the antiviral therapy with DAA 
should be checked.
Advantages of DAA administration in patients with liver 
cirrhosis:
– Possibility of oral administration.
– Short duration of treatment.
– High SVR and minimal adverse reactions [18, 26, 27, 
28].
– Decreased hepatic stiffness (fibrosis) in patients with 
SVR [15, 29].
– Improvement of liver function [30, 31].
Before initiating antiviral therapy, patients with liver 
cirrhosis should be examined in order to assess: presence / 
absence of esophageal varices, HCC and signs of hepatic de-
compensation (hepatic encephalopathy, ascites, etc.). In ge-
neral, the chance of performing SVR with DAA in patients 
with compensated cirrhosis (Child-Pugh A) is comparable 
to non-cirrhotic patients. However, there is a risk of decom-
pensation and acute liver failure during and after treatment 
[25]. Therefore, patients with advanced and decompensated 
cirrhosis should be treated and monitored in experienced 
centers, and the possibility of liver transplantation should 
be evaluated.
Patients with decompensated liver cirrhosis and advan-
ced liver fibrosis may have greater benefit from antiviral 
therapy after liver transplantation [19, 32].
The combination of sofosbuvir (SOF) / daclatasvir 
(DCV) with / without RBV and SOF / ledipasvir (LDV) 
with / without RBV clearly influences hepatocytolysis syn-
drome in patients with hepatic cirrhosis, the transaminase 
profile being significantly improved at the end of treatment 
(88-95% of patients had normal values), recording the bio-
chemical response [27, 33]. On the other hand, the combi-
nation of 2 DAA and RBV in patients with compensated li-
ver cirrhosis showed a higher efficacy (SVR 96%), compared 
to the schemes without RBV (SVR 88%)[33, 34].
RVS rates are decreased (82-87%) in patients with de-
compensated cirrhosis, especially in those with platelets 
<75000 [17, 27]. Studies have shown that the effectiveness 
of DAA therapy decreases with the degree of decompensati-
on of cirrhosis. Thus, the SOLAR-2 study evaluated the use 
of SOF / LDV and RBV in 329 patients with decompensated 
cirrhosis for 12 and 24 weeks. RVS rates at 12 weeks ran-
ged from 87% to 96% for Child Pugh B patients and 72-85% 
for Child Pugh C patients (genotype 1) [30]. Similar data 
were obtained in the ALLY-I study, patients being treated 
with SOF / DCV and RBV: the 12-week RVS rate was 96% 
in Child Pugh B patients and 56% in Child Pugh C patients 
[32, 35].
FDA (Food and Drug Administration) recommends 12 
weeks of RBV treatment in naive patients with compensated 
/ subcompensated cirrhosis [36]. The European Association 
for the Study of Liver Disease (EASL) recommends 24 we-
eks without RBV in patients with decompensated cirrhosis 
or those with pre / post liver transplant and 12 weeks with 
RBV in patients with compensated cirrhosis [37].
Afdhal N. et al. reported in a batch of 50  patients with 
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cirrhosis and HCV genotype 1 and 4 (60% Child Pugh B 
stage) in treatment with SOF and RBV, in 89% of patients a 
rapid viral response (RVR) was obtained ) at week 4 of treat-
ment and 97% at week 8 [18]. Out of a total of 108  patients 
with cirrhosis Child Pugh B genotype 1 and 4 treated with 
SOF / LDV and RBV, SVR was achieved in 89% of those 
who received 12 weeks of treatment [38]. It is remarkable 
that these rates of SVR are comparable to those for compen-
sated cirrhosis or even non-cirrhotic patients. DAA treat-
ment in patients with cirrhosis improves liver function by 
about 40% [2, 8, 31].
The combination paritaprevir (PTV) / ritonavir (RTV) / 
ombitasvir (OBV) plus dasabuvir (DVR) (3D regimen) was 
approved by the FDA in December 2014 for the treatment 
of HCV GT1 infection. The use of a 12-week PTV / OBV 
regimen stimulated with RTV with RBV (without DVR) in 
the treatment of HCV GT4 infection is studied in studies 
PEARL-1, AGATE-1 and AGATE-2. PEARL-1 is a study of 
91 naïve patients with cirrhosis, where all patients had SVR 
[39]. The AGATE-1 and AGATE-2 studies added the results 
of the PEARL-1 study by including patients with cirrhosis. 
All participants in the AGATE-1 study had cirrhosis, where 
97% SVR rates were reported (59/61) [40]. The AGATE-2 
study investigated patients with and without cirrhosis. In 
these cohorts, SVR rates of 97% (30/31) and 94% (94/100) 
were obtained. Extending treatment duration to 24 weeks 
did not increase SVR rate in patients with cirrhosis [41].
The OPTIMIST-2100 Phase III study had patients with 
HCV GT1 cirrhosis who were treated with SOF / simeprevir 
(SMV) for 12 weeks. RVS rates made up 83%  (86/103) [26]. 
In June 2016, the FDA approved the first pangenotypic 
regimen – SOF / velpatasvir (VEL), which introduced a new 
era of DAA therapy. This combination simplifies the mana-
gement of HCV infection treatment, because the need to 
determine the genotype before initiating antiviral therapy 
disappears. ASTRAL-1-5 studies have confirmed the pange-
notypic efficacy of SOF / VEL, as well as the efficacy of this 
regimen in HIV co-infection and in decompensated liver 
disease [42-44].  SOF / VEL with / without RBV has been 
shown to be an effective pangenotypic therapeutic option 
including in cirrhosis with HCV.
The American Association for the Study of Liver Disea-
ses (AASLD) and EASL recommend the administration of 
DAA regimens containing SOF with one of the following 
preparations: LDV, VEL, DCV in combination with RBV in 
patients with decompensated cirrhosis [2, 45]. 
The EASL recommends monitoring with abdominal ul-
trasound and alpha-fetoprotein (AFP) every 6 months, for 
early detection of HCC, for all patients with FibroScan> 9.5 
kPa (Metavir ≥ F3) [2]. The EACS (European AIDS Clinical 
Society) recommends surveillance only for cirrhotic pati-
ents, and FibroScan> 12.5 kPa is considered to indicate cir-
rhosis [46]. The occurrence of esophageal varices after SVR 
is rare, if varicose veins were not present at pre-treatment 
endoscopy. Endoscopic control for varicose veins is recom-
mended every 2 years after SVR in all patients with cirrhosis 
[26]. According to the Baveno VI statement, patients with 
compensated cirrhosis can avoid endoscopy provided they 
have platelets> 150,000 and FibroScan <20 kPa [47].
Invasive assessment of hepatic gradients of venous pre-
ssure before and after antiviral treatment showed a partial 
regression and normalization in most patients with portal 
hypertension who had SVR [48].
 Although, it has been shown that an SVR for antiviral 
treatment with DAA induces regression of liver cirrhosis and 
reduces the risk of mortality in cirrhotic patients, however, a 
significant risk for HCC development, cholangiocarcinoma 
and hepatic decompensation is still present, and long-term 
surveillance is mandatory. The results of the studies showed 
that, in these patients, the risk is significantly reduced com-
pared to those who failed the treatment [49-52].
Adverse events of DAA therapy
There are few studies describing the adverse events (AE) 
associated with DAA therapy in patients with liver cirrhosis. 
A study aimed at AE research included 102 patients (74% 
cirrhosis) with chronic HCV infection who underwent DAA 
therapy for 12 or 24 weeks. All patients received SVR. About 
90% of patients reported at least one AE associated with 
current treatment. The most common AEs reported were: 
fatigue (43%), headache (42%), neuropsychiatric symptoms 
(30%) and nausea (26%). Neuropsychiatric symptoms were 
more frequent in patients with previous antiviral treatment 
experience compared to naive patients [28].
Current guideline recommendations support the use of 
SOF-based DAA regimens in combination with LDV, VEL 
or DCV, with or without RBV, for the treatment of HCV 
infection in patients with cirrhosis. NS3 / 4 protease inhibi-
tors (Telaprevir, Boceprevir and Simeprevir) are not recom-
mended in cirrhosis because of their potential to aggravate 
liver disease. Apart from SOF that is mainly excreted by the 
kidneys, most DAAs are metabolized by the liver with bile 
excretion as a major pathway. Therefore, in patients with 
severe renal impairment (glomerular filtration rate <30 ml 
/ min), the administration of SOF is contraindicated and 
treatment of HCV infection should be postponed until after 
transplantation. At the same time, data from some studies 
suggest that SOF therapy can be used safely and effective-
ly in those with chronic kidney disease in stages 4 and 5, 
although patients with compensated liver disease were in-
cluded in the studies [53, 54].
Most EAs are related to the administration of RBV, so 
dose adjustment is needed. RBV-induced anemia may be 
moderate / severe, requiring dose adjustment or withdrawal 
of therapy with this preparation. In patients with decom-
pensated cirrhosis, it is suggested to administer RBV with 
an initial dose of 600 mg / day and increased depending on 
the tolerability of the patients.
It has been noted that, most commonly, adverse reacti-
ons to RBV manifest in patients with a higher degree of cir-
rhosis [16, 33, 55]. Studies in such patients have shown that 
RBV cancellation or dose reduction during treatment does 
not significantly influence the virological response to treat-
ment [30, 33, 56]. However, patients with hepatic cirrhosis 
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require hospitalization at the initiation of antiviral therapy, 
mainly due to complications caused by the disease.
The effectiveness of the PTV / RTV / OBV plus DVR 
combination is similar compared to LDV / SOF. However, 
the 3D regimen has two main disadvantages: the greater 
number of pills administered per day and the potential 
drug interactions [45]. The most common adverse events 
encountered during approval studies were: sleep disorders, 
nausea and pruritus. Increases of bilirubin to more than 
three times the upper limit of normal value were more 
frequently seen in patients with cirrhosis (9.7%). Relevant 
increases of ALAT were also noted. An Israel multicenter 
cohort study reported 7 patients who received PTV / RTV / 
OBV plus DVR and developed decompensation within 1 to 
8 weeks of starting therapy, and one patient died [57]. Due 
to these possible hepatotoxic effects and worsening of liver 
function in patients with advanced disease, this treatment 
cannot be recommended for patients with decompensated 
cirrhosis[58]. Patients with compensated cirrhosis who re-
ceive this regimen should monitor the clinical picture and 
symptoms of hepatic decompensation, being subjected to 
hepatic laboratory tests at the beginning and at least every 4 
weeks during therapy [45].
Hepatic fibrosis
Hepatic fibrosis, following chronic infection, is the most 
important factor related to HCV morbidity and mortality.
Hepatic fibrosis is a prognostic marker for the evolution 
of HCV infection. Thus, three types of fibrosis progression 
can be identified: the rapid progressive type (develops cir-
rhosis in less than 20 years), the intermediate type (develops 
cirrhosis between 20-50 years), the slow progressive type 
(without evolution towards cirrhosis or very slow evolution 
in more than 50 years) [59].
The researchers identified several factors that influence 
the regression or evolution of fibrosis. There were no signifi-
cant associations with the patient’s sex, age, race / ethnicity, 
other medical conditions or complications of cirrhosis [60, 
61]. However, diabetes and esophageal varicose veins have 
been associated with a lower likelihood of fibrosis improve-
ment [29].  
A meta-analysis of 111 studies revealed that fibrosis pro-
gression was nonlinear, with an estimated risk of cirrhosis 
of 16% and 41% after 20 and 30 years of infection respecti-
vely [61].  Other studies have also shown nonlinear develo-
pment, with major acceleration of fibrosis progression after 
age 50 [62].
When advanced fibrosis develops (stage F3 after the ME-
TAVIR scale), the risk of progression to cirrhosis is approxi-
mately 10% per year.
Studies were conducted with monitoring of the fibrosis 
degree in cirrhosis with HCV after treatment with DAA ob-
tained SVR. Thus, in a study in which 65 people with cir-
rhosis were evaluated after DAA treatment, 55% showed 
improvement and 45% of the fibrosis remained unchanged. 
It was found that the average time to improvement was 2.5-
3.0 years from the time of initiation of therapy, indicating 
that those with less severe hepatic injury have a faster im-
provement [15].
HCV infection has increased the interest for the study 
of the cellular and molecular mechanism of hepatic fibrosis, 
with a view to identifying effective therapeutic, etiological, 
pathogenic and antifibrotic means.
Hepatocellular carcinoma
Patients who develop liver cirrhosis prior to initiation of 
antiviral therapy should be maintained in the HCC surveil-
lance program because the risk of malignant development is 
high, even if elimination of SVR infection is achieved.
The appearance in the liver cirrhosis of regenerative 
nodules or hyperplastic nodules is the main alarm signal, 
because following genetic changes that occur during repeti-
tive cell proliferation, these nodules change into dysplastic 
nodules, a process that leads to liver damage [63].
Numerous studies have been carried out over the years, 
targeting patients who have developed CHC following anti-
viral therapies [28, 37-39].
In the study that included 103 patients with a history of 
HCC in a previously treated (surgical) history with a com-
plete response (absence of characteristic nodules), they re-
ceived DAA treatment. Patients pretreated with IFN in the 
background were not included in the study. After a moni-
toring of approximately 6 months, 18 patients had recur-
rence of HCC with the development of the characteristic 
intrahepatic tumor nodules [64].
On the other hand, another study conducted on 819 
patients evaluated the risk of developing HCC after DAA 
treatment compared to patients treated with IFN. It was 
found that rates of HCC development did not differ be-
tween patients treated with DAA and those receiving IFN. 
At the same time, all patients who developed HCC were in 
the stage of liver cirrhosis [65].
Data from some studies have shown that patients with 
cirrhosis and HCC have SVR rates (74%) lower than pa-
tients with cirrhosis, but without HCC (91%) [66, 67].
There was also a correlation between HCC and high 
levels of alpha-fetoprotein, platelet count ≤110 x109 / l, ad-
vanced fibrosis (F4), adverse effects on more common anti-
viral therapy, RVS rate in comparison with lower DAA with 
those who do not develop HCC (87.3 vs 95.5%) [68].
 Until recently, the category of patients with HCC as-
sociated with viral hepatitis C had a lower survival rate than 
those with HCC of other etiology, due to the lack of effec-
tive treatment for the underlying hepatitis C virus infection, 
but the new interferon-free therapies significantly improved 
these figures.
Treatment with DAA in patients with chronic HCV hep-
atitis does not increase the risk of developing HCC, so this 
treatment is considered a method of preventing the progres-
sion of the disease to cirrhosis and HCC.
Conclusions
1. Interferon-free treatment simplified therapeutic be-
havior and exponentially reduced adverse effects.
2. New generations of drugs (DAAs), which provide 
high SVR, are the best and reasonable option including for 
patients with advanced liver cirrhosis.
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3.  Based on the results presented in different clinical stu-
dies, it is recommended to initiate DAA therapy earlier in 
order to ensure a faster decrease in liver stiffness after treat-
ment.
4.  The choice of antiviral treatment regimen and its du-
ration is individualized according to the degree of fibrosis, 
genotype, concomitant diseases and adverse effects that may 
occur.
5.  In patients with hepatic cirrhosis, DAA therapy has 
been shown to be the most effective prevention for the de-
velopment of hepatocellular carcinoma.
6. After obtaining SVR, patients with liver cirrhosis, 
however, present a significant risk for developing hepatic 
decompensation, so long-term surveillance is mandatory.
7. The risk of HCC and mortality is significantly redu-
ced, but not completely eliminated in cirrhotic patients who 
have obtained SVR, as opposed to untreated patients and 
patients who do not get SVR, especially in the presence of 
other causes of hepatic impairment: metabolic syndrome, 
consumption of alcohol and co-infection with HBV / HIV.
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